Summary
Global Markets Direct’s, ‘Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016’, provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
- The report reviews pipeline therapeutics for Acute Respiratory Distress Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Respiratory Distress Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Acute Respiratory Distress Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Altor BioScience Corporation
Athersys, Inc.
Faron Pharmaceuticals Oy
FirstString Research, Inc.
GlaxoSmithKline Plc
Global Blood Therapeutics, Inc.
Hydra Biosciences, Inc.
Phylogica Limited
S-Evans Biosciences, Inc.
Savara Inc.
Silence Therapeutics Plc
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Respiratory Distress Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Acute Respiratory Distress Syndrome - Overview 10
Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis 11
Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies 12
Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes 13
Acute Respiratory Distress Syndrome - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Acute Respiratory Distress Syndrome - Products under Development by Companies 17
Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes 18
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development 19
Altor BioScience Corporation 19
Athersys, Inc. 20
Faron Pharmaceuticals Oy 21
FirstString Research, Inc. 22
GlaxoSmithKline Plc 23
Global Blood Therapeutics, Inc. 24
Hydra Biosciences, Inc. 25
Phylogica Limited 26
S-Evans Biosciences, Inc. 27
Savara Inc. 28
Silence Therapeutics Plc 29
Acute Respiratory Distress Syndrome - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
ALT-836 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
BIO-10901 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
BIO-11006 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
GBT-440 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
GSK-2586881 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
GSK-2862277 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
HC-067047 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
interferon beta-1a - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
LT-0011 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
molgramostim - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
PF-05285401 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
PYC-35 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
PYC-36 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
PYC-38 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
PYC-98 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
S-1229 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
SAN-101 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Acute Respiratory Distress Syndrome - Dormant Projects 83
Acute Respiratory Distress Syndrome - Discontinued Products 86
Acute Respiratory Distress Syndrome - Product Development Milestones 87
Featured News & Press Releases 87
May 25, 2016: First patient dosed in Savaras pivotal trial for PAP 87
Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation 87
Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS 88
Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome 88
Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP 89
Aug 09, 2015: Serendex to initiate first phase II clinical trial 90
Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November 90
May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced 91
May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical’s inhalable biological drug for treatment of severe pulmonary diseases 91
May 10, 2015: Positive topline data from Serendex phase I clinical trial 92
Feb 27, 2015: Serendex submits phase I application 93
Feb 13, 2015: Serendex partners up with leading German lung center 93
Jan 28, 2015: Serendex receives positive scientific advice from EMA 94
Jan 22, 2015: Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition 94
Dec 10, 2014: Serendex Registers First Sale Of Molgradex 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 96
Disclaimer 97
List of Tables
Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2016 10
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corporation, H2 2016 19
Acute Respiratory Distress Syndrome - Pipeline by Athersys, Inc., H2 2016 20
Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2 2016 21
Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H2 2016 22
Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016 23
Acute Respiratory Distress Syndrome - Pipeline by Global Blood Therapeutics, Inc., H2 2016 24
Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences, Inc., H2 2016 25
Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H2 2016 26
Acute Respiratory Distress Syndrome - Pipeline by S-Evans Biosciences, Inc., H2 2016 27
Acute Respiratory Distress Syndrome - Pipeline by Savara Inc., H2 2016 28
Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Stage and Target, H2 2016 32
Number of Products by Stage and Mechanism of Action, H2 2016 34
Number of Products by Stage and Route of Administration, H2 2016 36
Number of Products by Stage and Molecule Type, H2 2016 38
Acute Respiratory Distress Syndrome - Dormant Projects, H2 2016 83
Acute Respiratory Distress Syndrome - Dormant Projects (Contd..1), H2 2016 84
Acute Respiratory Distress Syndrome - Dormant Projects (Contd..2), H2 2016 85
Acute Respiratory Distress Syndrome - Discontinued Products, H2 2016 86
List of Figures
Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2016 10
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Top 10 Targets, H2 2016 31
Number of Products by Stage and Top 10 Targets, H2 2016 31
Number of Products by Top 10 Mechanism of Actions, H2 2016 33
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 33
Number of Products by Routes of Administration, H2 2016 35
Number of Products by Stage and Routes of Administration, H2 2016 35
Number of Products by Molecule Types, H2 2016 37
Number of Products by Stage and Molecule Types, H2 2016 37
